Canaccord lowered the firm’s price target on Regulus to $11 from $12 and keeps a Buy rating on the shares. The firm noted they announced topline data from Cohort 2 in its Ph1b MAD study of RGLS8429 for ADPKD with the totality of the news being highly encouraging and sets shares up nicely into the next update from cohort 3 mid-year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGLS:
